[8-K] Lucid Diagnostics Inc. Reports Material Event
Lucid Diagnostics Inc. announced it furnished a press release reporting financial results and a business update for the fiscal quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference into this Form 8-K. The company disclosed that the information under Items 2.02 and 7.01, including the exhibit, is furnished and shall not be deemed "filed" under the Exchange Act for purposes of Section 18, nor incorporated by reference in other filings except by specific reference. The filing identifies the registrant as Lucid Diagnostics Inc., trading as LUCD on The Nasdaq Stock Market, and indicates the company qualifies as an emerging growth company.
Lucid Diagnostics Inc. ha reso noto di aver diffuso un comunicato stampa con i risultati finanziari e un aggiornamento aziendale per il trimestre fiscale chiuso il 30 giugno 2025. Il comunicato è allegato come Exhibit 99.1 ed è richiamato per riferimento nel presente Form 8-K. La società ha dichiarato che le informazioni relative agli Items 2.02 e 7.01, incluso l'esibito, sono fornite e non devono essere considerate "presentate" ai sensi dello Exchange Act per gli scopi della Sezione 18, né incorporate per riferimento in altri documenti salvo espressa indicazione. Il documento identifica la registrante come Lucid Diagnostics Inc., quotata con il simbolo LUCD sul Nasdaq Stock Market, e indica che la società rientra nella categoria di emerging growth company.
Lucid Diagnostics Inc. anunció que remitió un comunicado de prensa con los resultados financieros y una actualización de negocio correspondientes al trimestre fiscal cerrado el 30 de junio de 2025. El comunicado se adjunta como Exhibit 99.1 y se incorpora por referencia en este Form 8-K. La compañía señaló que la información relativa a los Items 2.02 y 7.01, incluido el anexo, se suministra y no deberá considerarse "presentada" conforme al Exchange Act a los efectos de la Sección 18, ni incorporarse por referencia en otras presentaciones salvo mención expresa. El expediente identifica al registrante como Lucid Diagnostics Inc., que cotiza bajo el símbolo LUCD en The Nasdaq Stock Market, e indica que la compañía califica como emerging growth company.
Lucid Diagnostics Inc.는 2025년 6월 30일로 종료된 회계분기의 재무실적 및 사업 업데이트를 보고하는 보도자료를 제공했다고 발표했습니다. 해당 보도자료는 Exhibit 99.1로 첨부되어 이 Form 8-K에 의해 참조로 포함됩니다. 회사는 Items 2.02 및 7.01에 따른 정보(해당 전시물 포함)가 제공되었으며 Exchange Act상 Section 18의 목적을 위해 "제출된 것으로 간주되지 않습니다"라고 밝혔고, 명시적 참조가 없는 한 다른 제출 문서에 참조로 포함되지 않는다고 공시했습니다. 신고인은 Lucid Diagnostics Inc.이며, LUCD라는 심볼로 The Nasdaq Stock Market에서 거래되고 있고, 회사는 emerging growth company에 해당한다고 표시되어 있습니다.
Lucid Diagnostics Inc. a annoncé avoir diffusé un communiqué de presse faisant état des résultats financiers et d'une mise à jour commerciale pour le trimestre clos le 30 juin 2025. Le communiqué est joint en tant que Exhibit 99.1 et est incorporé par référence dans ce Form 8-K. La société a indiqué que les informations relevant des Items 2.02 et 7.01, y compris l'annexe, sont fournies et ne doivent pas être considérées comme "déposées" au regard de l'Exchange Act pour l'application de la Section 18, ni incorporées par référence dans d'autres dépôts sauf indication expresse. Le dossier identifie le déclarant comme Lucid Diagnostics Inc., cotée sous le symbole LUCD sur The Nasdaq Stock Market, et précise que la société a le statut d'emerging growth company.
Lucid Diagnostics Inc. gab bekannt, eine Pressemitteilung mit den Finanzergebnissen und einem Geschäftsupdate für das zum 30. Juni 2025 beendete Quartal herausgegeben zu haben. Die Pressemitteilung ist als Exhibit 99.1 beigefügt und wird durch Bezugnahme in dieses Form 8-K einbezogen. Das Unternehmen erklärte, dass die Angaben unter den Items 2.02 und 7.01, einschließlich des Anhangs, bereitgestellt werden und nicht als "eingereicht" im Sinne des Exchange Act für die Zwecke von Section 18 angesehen werden dürfen, noch in andere Einreichungen durch Verweis aufgenommen werden, es sei denn durch ausdrückliche Nennung. Die Einreichung identifiziert den Registranten als Lucid Diagnostics Inc., die unter dem Kürzel LUCD an der Nasdaq Stock Market gehandelt wird, und weist darauf hin, dass das Unternehmen als emerging growth company qualifiziert.
- Company furnished a press release announcing financial results and a business update for the quarter ended June 30, 2025
- Press release attached as Exhibit 99.1, providing a direct source for investors to review results and updates
- Registrant confirmed Nasdaq listing under the symbol LUCD and identified as an emerging growth company
- None.
Insights
TL;DR This 8-K furnishes an earnings press release and a business update; the disclosure is routine and informational.
The filing notifies investors that Lucid Diagnostics has issued a press release with quarter-end financial results and a business update, attached as Exhibit 99.1. Because the company specifies the disclosures are "furnished" and not "filed," the legal incorporation by reference is limited. For analysts, the 8-K itself contains no financial metrics; investors must review the attached press release for material performance data. The filing confirms LUCD’s Nasdaq listing and emerging growth company status, which may affect certain reporting and compliance timelines.
TL;DR The Form 8-K documents routine disclosure practice; legal treatment of the press release is explicitly limited.
The company follows standard disclosure protocol by furnishing — rather than filing — the press release and business update, explicitly stating limited incorporation by reference. This approach limits Section 18 liability for the content of the press release unless later expressly referenced in another filing. The 8-K itself conveys no substantive operational or financial detail; governance stakeholders should review Exhibit 99.1 to assess any changes to strategy, results, or forward-looking statements.
Lucid Diagnostics Inc. ha reso noto di aver diffuso un comunicato stampa con i risultati finanziari e un aggiornamento aziendale per il trimestre fiscale chiuso il 30 giugno 2025. Il comunicato è allegato come Exhibit 99.1 ed è richiamato per riferimento nel presente Form 8-K. La società ha dichiarato che le informazioni relative agli Items 2.02 e 7.01, incluso l'esibito, sono fornite e non devono essere considerate "presentate" ai sensi dello Exchange Act per gli scopi della Sezione 18, né incorporate per riferimento in altri documenti salvo espressa indicazione. Il documento identifica la registrante come Lucid Diagnostics Inc., quotata con il simbolo LUCD sul Nasdaq Stock Market, e indica che la società rientra nella categoria di emerging growth company.
Lucid Diagnostics Inc. anunció que remitió un comunicado de prensa con los resultados financieros y una actualización de negocio correspondientes al trimestre fiscal cerrado el 30 de junio de 2025. El comunicado se adjunta como Exhibit 99.1 y se incorpora por referencia en este Form 8-K. La compañía señaló que la información relativa a los Items 2.02 y 7.01, incluido el anexo, se suministra y no deberá considerarse "presentada" conforme al Exchange Act a los efectos de la Sección 18, ni incorporarse por referencia en otras presentaciones salvo mención expresa. El expediente identifica al registrante como Lucid Diagnostics Inc., que cotiza bajo el símbolo LUCD en The Nasdaq Stock Market, e indica que la compañía califica como emerging growth company.
Lucid Diagnostics Inc.는 2025년 6월 30일로 종료된 회계분기의 재무실적 및 사업 업데이트를 보고하는 보도자료를 제공했다고 발표했습니다. 해당 보도자료는 Exhibit 99.1로 첨부되어 이 Form 8-K에 의해 참조로 포함됩니다. 회사는 Items 2.02 및 7.01에 따른 정보(해당 전시물 포함)가 제공되었으며 Exchange Act상 Section 18의 목적을 위해 "제출된 것으로 간주되지 않습니다"라고 밝혔고, 명시적 참조가 없는 한 다른 제출 문서에 참조로 포함되지 않는다고 공시했습니다. 신고인은 Lucid Diagnostics Inc.이며, LUCD라는 심볼로 The Nasdaq Stock Market에서 거래되고 있고, 회사는 emerging growth company에 해당한다고 표시되어 있습니다.
Lucid Diagnostics Inc. a annoncé avoir diffusé un communiqué de presse faisant état des résultats financiers et d'une mise à jour commerciale pour le trimestre clos le 30 juin 2025. Le communiqué est joint en tant que Exhibit 99.1 et est incorporé par référence dans ce Form 8-K. La société a indiqué que les informations relevant des Items 2.02 et 7.01, y compris l'annexe, sont fournies et ne doivent pas être considérées comme "déposées" au regard de l'Exchange Act pour l'application de la Section 18, ni incorporées par référence dans d'autres dépôts sauf indication expresse. Le dossier identifie le déclarant comme Lucid Diagnostics Inc., cotée sous le symbole LUCD sur The Nasdaq Stock Market, et précise que la société a le statut d'emerging growth company.
Lucid Diagnostics Inc. gab bekannt, eine Pressemitteilung mit den Finanzergebnissen und einem Geschäftsupdate für das zum 30. Juni 2025 beendete Quartal herausgegeben zu haben. Die Pressemitteilung ist als Exhibit 99.1 beigefügt und wird durch Bezugnahme in dieses Form 8-K einbezogen. Das Unternehmen erklärte, dass die Angaben unter den Items 2.02 und 7.01, einschließlich des Anhangs, bereitgestellt werden und nicht als "eingereicht" im Sinne des Exchange Act für die Zwecke von Section 18 angesehen werden dürfen, noch in andere Einreichungen durch Verweis aufgenommen werden, es sei denn durch ausdrückliche Nennung. Die Einreichung identifiziert den Registranten als Lucid Diagnostics Inc., die unter dem Kürzel LUCD an der Nasdaq Stock Market gehandelt wird, und weist darauf hin, dass das Unternehmen als emerging growth company qualifiziert.
FAQ
What did Lucid Diagnostics (LUCD) disclose in this 8-K?
Is the press release in the 8-K considered "filed" with the SEC?
Where does Lucid Diagnostics trade and what is the ticker?
Does the filing indicate Lucid Diagnostics is an emerging growth company?
Where can I find the detailed financial results referenced in the 8-K?
